Nasser Altorki, MD - Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/CDB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Research and clinical practice continue to build on the success achieved to date with cancer immunotherapy and to refine rational strategies to expand its benefits to more patients, including in curative-intent settings. Immunotherapy has started to radically transform the multimodal approach to treatment of resectable stage I-III NSCLC. Recently, highly positive data have emerged from the first few phase 3 trials evaluating neoadjuvant and adjuvant immunotherapies in resectable lung cancer, leading to regulatory approvals and new standards of care in these settings. What do these advances mean for thoracic surgeons, medical oncologists, pulmonologists, and other multidisciplinary specialists, and what changes in practice are needed? What challenges and unanswered questions remain? This PeerView educational activity, based on a recent live symposium, brings together top experts to discuss new, practice-changing evidence, the implications and applicability of the latest data to practice, and how to achieve better partnerships across disciplines to facilitate the incorporation of immunotherapies into new standards of care to improve outcomes and quality of life for patients with stage I-III NSCLC. Upon completion of this activity, participants should be better able to: Discuss the mechanistic and biologic rationale for using immunotherapy as a component of multimodal therapy in early-stage lung cancer and key clinical trials evaluating immunotherapies in these settings; Summarize the latest findings on surrogate endpoints, such as pathologic response criteria, to assess treatment response and evaluate the prognosis of patients with resectable lung cancer who are receiving immunotherapy; Identify patients with resectable NSCLC who are eligible for perioperative immunotherapy, considering the benefits/limitations and surgical implications based on an understanding of the latest evidence and persisting misperceptions; and Collaborate with the multidisciplinary team to integrate immunotherapy into individualized, multimodal treatment plans for eligible patients with stage I-III resectable NSCLC.